TY - JOUR
T1 - Betaine and nonalcoholic steatohepatitis
T2 - Back to the future?
AU - Mukherjee, Sandeep
N1 - Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2011/8/28
Y1 - 2011/8/28
N2 - Nonalcoholic steatohepatitis (NASH) is an important indication for liver transplantation in many Western countries. Obesity and insulin resistance are the two most common risk factors for NASH, which can lead to recurrent NASH after liver transplantation. There is currently no approved therapy for NASH, and treatment is directed at risk factor modifcation and lifestyle changes. Betaine has been used for NASH, with mixed results, and may show promise in conjunction with other agents in clinical trials.
AB - Nonalcoholic steatohepatitis (NASH) is an important indication for liver transplantation in many Western countries. Obesity and insulin resistance are the two most common risk factors for NASH, which can lead to recurrent NASH after liver transplantation. There is currently no approved therapy for NASH, and treatment is directed at risk factor modifcation and lifestyle changes. Betaine has been used for NASH, with mixed results, and may show promise in conjunction with other agents in clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=80053910713&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80053910713&partnerID=8YFLogxK
U2 - 10.3748/wjg.v17.i32.3663
DO - 10.3748/wjg.v17.i32.3663
M3 - Article
C2 - 21990946
AN - SCOPUS:80053910713
VL - 17
SP - 3663
EP - 3664
JO - World Journal of Gastroenterology
JF - World Journal of Gastroenterology
SN - 1007-9327
IS - 32
ER -